Nurix Therapeutics (NRIX) AI Stock Analysis

• Market Cap: $892.72M
• Dividend Yield: N/A
• Average Volume (3M): 817.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.16
• Revenue Growth: -30.25%
• EPS Growth: -5.92%
• Country: US
• Employees: 286
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.67
• Shares Outstanding: 76,235,596
• 10 Day Avg. Volume: 777,613
• 30 Day Avg. Volume: 817,034
• PEG Ratio: -0.14
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.50
• Enterprise Value/Market Cap: 0.62
• Enterprise Value/Revenue: 2.39
• Enterprise Value/Gross Profit: 12.48
• Enterprise Value/Ebitda: -0.73
• 1Y Price Target: $29.50
• Price Target Upside: 137.14% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 15

• Rating: 56 Neutral
• Price Target: $12.00 ▼(-3.54%Downside)

The overall stock score reflects significant strengths and challenges. The positive clinical trial results are a major strength, indicating potential future growth. However, ongoing financial challenges, including negative profitability and cash flow, weigh heavily on the score. Technical analysis shows mixed signals, with no clear trend, and the valuation remains unattractive due to unprofitability.

Positive Factors

Clinical Trial Results

NX-5948 elicited an 80.9% overall response rate in 47 evaluable CLL patients, which is highly favorable.

Safety Profile

No new patients developed atrial fibrillation, which is a positive safety indicator for NX-5948.

Strategic Partnerships

NRIX announced that partner SAN FP exercised their option to license NRIX's STAT6 program, including development candidate NX-3911, providing a $15M license fee.

Negative Factors

Competitive Environment

The path to value creation for bexobrutideg in CLL is complicated by a tough competitive environment and development path.

Market Differentiation

While an undifferentiated, second-to-market BTK degrader still has real value, the stock will stay range-bound pending differentiation vs. ONC, clarity on the development path and timelines, and/or gaining a strategic partnership.

Nurix Therapeutics Business Overview & Revenue Model

Company Description

Nurix Therapeutics, Inc. (NRIX) is a biopharmaceutical company based in the United States that focuses on the discovery, development, and commercialization of therapies targeting the ubiquitin proteasome system. The company operates in the biotechnology sector and primarily develops products that aim to treat cancer and other challenging diseases through the modulation of protein levels using its proprietary drug discovery platform, DELigase. Nurix's core products are in the preclinical and clinical stages of development, targeting various oncology and immuno-oncology indications.

How the Company Makes Money

Nurix Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical companies. These agreements often include upfront payments, research funding, milestone payments, and potential royalties on sales of products developed through joint efforts. The company leverages its proprietary technology platform to engage in partnerships that enhance its drug discovery capabilities and expand its pipeline. Significant collaborations with leading pharmaceutical companies contribute to its earnings and support the ongoing research and development of its therapeutic candidates.

Nurix Therapeutics Financial Statement Overview

Summary

Nurix Therapeutics faces significant challenges in achieving profitability and sustainable cash flow. The company shows a strong equity position with minimal leverage, but ongoing operational and profitability concerns are evident in the negative margins and cash flow figures.

Income Statement

Nurix Therapeutics has shown an inconsistent revenue trend with notable fluctuations. The TTM data indicates a gross profit margin of 85.39%, reflecting efficient cost management relative to revenue. However, the company is struggling with profitability, as indicated by a negative net profit margin of -369.41%. EBIT and EBITDA margins are also negative, highlighting ongoing operational challenges.

Balance Sheet

The company displays a strong equity position, with an equity ratio of 78.19% in the TTM, indicating low leverage and a strong reliance on equity financing. However, the debt-to-equity ratio stands at 0.06, which is relatively low, suggesting minimal debt use. Return on Equity (ROE) remains negative due to ongoing net losses, impacting overall financial stability.

Cash Flow

Operating cash flow is negative, reflecting ongoing cash burn from operations. The free cash flow growth rate remains concerning, with continued negative figures indicating challenges in generating cash from operations. However, the operating cash flow to net income ratio is slightly improving, suggesting potential operational efficiency gains.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	56.42M	54.55M	76.99M	38.63M	29.75M	17.82M
Gross Profit	44.05M	38.12M	-112.16M	27.82M	23.67M	-48.67M
EBITDA	-214.00M	-196.60M	-141.41M	-173.06M	-111.80M	-62.80M
Net Income	-208.40M	-193.57M	-143.95M	-166.04M	-117.19M	-43.24M
Balance Sheet
Total Assets	615.04M	669.34M	355.60M	416.76M	476.77M	396.34M
Cash, Cash Equivalents and Short-Term Investments	549.68M	609.58M	287.91M	309.14M	295.72M	281.15M
Total Debt	26.62M	28.30M	30.61M	11.96M	13.04M	0.00
Total Liabilities	134.13M	142.35M	155.10M	113.06M	134.47M	106.07M
Stockholders Equity	480.92M	526.99M	200.49M	303.70M	342.30M	290.27M
Cash Flow
Free Cash Flow	-201.59M	-181.86M	-89.77M	-172.05M	-90.03M	-4.63M
Operating Cash Flow	-191.72M	-172.58M	-81.36M	-159.81M	-84.36M	-80.00K
Investing Cash Flow	-267.69M	-257.71M	68.30M	27.20M	-108.25M	-254.40M
Financing Cash Flow	485.52M	485.67M	3.22M	117.19M	153.88M	339.02M

Nurix Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.44
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRIX, the sentiment is Positive. The current price of 12.44 is above the 20-day moving average (MA) of 12.01, above the 50-day MA of 11.11, and below the 200-day MA of 17.28, indicating a neutral trend. The MACD of 0.20 indicates Positive momentum. The RSI at 60.19 is Neutral, neither overbought nor oversold. The STOCH value of 45.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NRIX.

Nurix Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTLA	59 Neutral	$1.02B	―	-57.92%	―	-13.37%	2.57%
NRIX	56 Neutral	$892.72M	―	-64.16%	―	-30.25%	-5.92%
MLYS	53 Neutral	$892.90M	―	-56.31%	―	―	-106.10%
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
ARVN	50 Neutral	$556.92M	―	-35.41%	―	―	―
RCUS	48 Neutral	$885.20M	―	-63.17%	―	-40.51%	-35.07%
IOVA	48 Neutral	$581.05M	―	-51.85%	―	11070.12%	32.07%

Nurix Therapeutics Corporate Events

Nurix Therapeutics Announces Positive Phase 1 Trial Results

On June 12, 2025, Nurix Therapeutics announced positive clinical data from its Phase 1 trial of bexobrutideg (NX-5948) at the European Hematology Association Congress. The data showed an objective response rate of 80.9% in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and 84.2% in patients with Waldenström macroglobulinemia (WM), with bexobrutideg demonstrating a favorable safety profile and potential as a treatment for patients with high unmet medical needs. The company plans to initiate pivotal trials in 2025, reinforcing its scientific leadership in targeted protein degradation.

The most recent analyst rating on (NRIX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.

Nurix Therapeutics Holds 2025 Annual Stockholders Meeting

On May 19, 2025, Nurix Therapeutics held its virtual 2025 Annual Meeting of Stockholders, where approximately 85.33% of the voting power was represented. Stockholders voted to elect three Class II directors, ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm, and approve the compensation of named executive officers on a non-binding advisory basis.

The most recent analyst rating on (NRIX) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Nurix Therapeutics stock, see the NRIX Stock Forecast page.